Amplia's Narmafotinib Shows Unprecedented Complete Response Rate in Pancreatic Cancer Trial
Event summary
- Independent analysis confirms 7.8% complete response rate in ACCENT trial, up from previously reported 6.3%.
- Median overall survival improved to 11.1 months, a 2-month gain over standard chemotherapy.
- ACCENT trial data selected for presentation at the 2026 AACR annual meeting.
- No additional toxicity observed with narmafotinib-chemotherapy combination.
- Four patients remain on study, with one approaching 24 months of treatment.
The big picture
Amplia's narmafotinib is emerging as a potential game-changer in pancreatic cancer treatment, where complete response rates have historically been dismal. The drug's ability to improve survival without added toxicity positions it favorably against existing standards like gemcitabine-Abraxane and newer combinations like NALIRIFOX. The upcoming AACR presentation will be critical for validating these findings in the scientific community.
What we're watching
- Clinical Validation
- Whether the unprecedented complete response rate can be replicated in larger studies.
- Regulatory Pathway
- The pace at which Amplia advances narmafotinib toward potential approval.
- Competitive Positioning
- How these results compare to emerging pancreatic cancer therapies in development.
Related topics